Skip to main content
TipRanks
Go Ultimate75% OFF

Allergy Therapeutics (AGYTF) Stock Price & Analysis

2 Followers

AGYTF Stock Chart & Stats

$0.14$0.00(0.00%)
At close: 4:00 PM EST
$0.125$0.15May 7Jun 2Jun 26
Day’s Range
$0.14 - $0.14
52-Week Range
$0.11 - $0.15
Previous Close
$0.14
Volume
N/A
Average Volume (3M)
0
Market Cap
$117.06M
Enterprise Value
$478.24M
Total Cash (Recent Filing)
$24.20M
Total Debt (Recent Filing)
$67.00M
Price to Earnings (P/E)
―
Beta
-2.03
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Underlying-cause Allergy Treatments

A focus on allergy immunotherapy and diagnosis addresses the underlying disease rather than providing only symptom relief. That positioning can support differentiated products, recurring clinical demand, and a clearer specialty-pharmaceutical role over the next several quarters.

Revenue Resilience

Revenue resilience provides evidence that the company retains demand for its products despite severe profitability pressure. The 2026 rebound is modest, but maintaining the top line can preserve commercial scale and provide a base for future operational improvement.

Cash-loss Alignment

Cash outflow being broadly aligned with reported losses gives a clearer view of the company’s underlying economics than results heavily distorted by non-cash charges. This does not remove funding risk, but it makes performance and required operational improvements more transparent.

Bears Say

Severe Profitability Deterioration

The sharp gross-margin compression and very deep net losses indicate that revenue is currently converting into substantially weaker earnings than in 2021. Unless margins recover, the company will struggle to fund growth internally and may remain dependent on external capital.

Persistent Cash Burn

Repeated negative operating and free cash flow shows that the business has not yet reached self-sustaining cash generation. Continued annual cash consumption can reduce strategic flexibility, increase reliance on financing, and make recovery more sensitive to execution and funding conditions.

Negative Equity And Rising Debt

Negative equity combined with a large increase in debt signals substantial balance-sheet strain and limited financial flexibility. Higher leverage can constrain investment choices, increase dependence on continued funding, and leave the company less able to absorb further losses.

Allergy Therapeutics News

AGYTF FAQ

What was Allergy Therapeutics’s price range in the past 12 months?
Allergy Therapeutics lowest stock price was $0.11 and its highest was $0.15 in the past 12 months.
What is Allergy Therapeutics’s market cap?
Allergy Therapeutics’s market cap is $117.06M.
When is Allergy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Allergy Therapeutics’s earnings last quarter?
Allergy Therapeutics released its earnings results on Nov 13, 2026. The company reported -$0.007 earnings per share for the quarter.
Is Allergy Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Allergy Therapeutics pay dividends?
Allergy Therapeutics does not currently pay dividends.
What is Allergy Therapeutics’s EPS estimate?
Allergy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allergy Therapeutics have?
Allergy Therapeutics has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics’s price movement after its last earnings report?
Allergy Therapeutics reported an EPS of -$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Allergy Therapeutics?
Currently, no hedge funds are holding shares in AGYTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology